Irinotecan is an effective drug for advanced colorectal cancer, as a single agent ([@bib34]) or in combination with a fluoropyrimidine ([@bib6]; [@bib26]; [@bib16]), with or without a monoclonal antibody ([@bib31]). Irinotecan is a pro-drug, and its active metabolite SN-38 has both antitumour activities and toxicities ([@bib33]; [@bib37]). SN-38 is inactivated into SN-38 glucuronide (SN-38G) mainly by UDP-glucuronosyltransferase 1A1 (UGT1A1) ([@bib15]).

Genetic polymorphisms in *UGT1A1,* such as *UGT1A1\*28* in Caucasians and Asians and *UGT1A1\*6* only in Asians, contribute to interpatient variability in the pharmacokinetics and toxicities of irinotecan, particularly severe neutropenia ([@bib1]; [@bib11]; [@bib25]; [@bib13]; [@bib3]). In 2005, the US Food and Drug Administration recommended that the package insert of irinotecan be amended to encourage the use of a reduced starting dose in patients homozygous for *UGT1A1\*28* (\**28*/\**28*). In 2008, the Ministry of Health, Labour, and Welfare of Japan likewise recommended that the package insert be revised to warn of the risk of severe irinotecan-related neutropenia in Japanese patients who are either homozygous for *UGT1A1\*6* or *UGT1A1\*28* or heterozygous for both *UGT1A1\*6* and *UGT1A1\*28*. Subsequently, diagnostic genotyping for the *UGT1A1\*6* and *UGT1A1\*28* was approved in Japan and covered by health insurance.

However, factors other than the *UGT1A1* genotype may contribute to irinotecan-induced severe toxicity such as neutropenia and diarrhoea. Other non-genetic factors, such as organ functions, age, gender, co-morbidities, and performance status (PS), should therefore be comprehensively considered in predicting the risk of severe irinotecan-related toxicities ([@bib11]; [@bib22]; [@bib28]; [@bib12]; [@bib17]; [@bib19]).

We designed a prospective observational study to evaluate the effects of *UGT1A1* genotypes and non-genetic factors on the efficacy and safety of irinotecan-based regimens in Japanese patients with advanced colorectal cancer. Our primary objective was to demonstrate non-inferiority of the response to irinotecan-based regimens in terms of progression-free survival between patients harbouring *UGT1A1\*6* or *UGT1A1\*28* and patients without these polymorphisms. The secondary objective was to evaluate the relation between *UGT1A1* genotype and the safety of irinotecan-based regimens. The results of the final analysis of outcomes will be available in 2015; however, we now report the results of a planned interim analysis of safety data from 1312 patients and describe the development of a nomogram for predicting the risk of irinotecan-induced severe neutropenia, with external validation using an independent cohort of 350 patients.

Materials and methods
=====================

Study design and patient eligibility
------------------------------------

This multicentre, open-label, prospective, non-interventional, observational study was conducted at 299 sites in Japan. Eligible patients had to (1) have a histologically confirmed diagnosis of adenocarcinoma of the colon or rectum, (2) have advanced or metastatic disease that was not amenable to curative resection, (3) undergo genotyping for *UGT1A1\*1, \*6* and *\*28* before treatment, and (4) be scheduled to receive FOLFIRI ([@bib26]) (folinic acid (200 mg m^−2^) and irinotecan (150 mg m^−2^) and then a bolus injection of 5-fluorouracil (400 mg m^−2^) on day 1 and a continuous infusion of 5-fluorouracil (2400 mg m^−2^) over 46 h, repeated every 2 weeks), IRIS ([@bib26]; [@bib16]) (irinotecan (125 mg m^−2^) on days 1 and 15 and S-1 (40--60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks), SIR ([@bib6]) (irinotecan (150 mg m^−2^) on day 1 and S-1 twice daily for 2 weeks, repeated every 3 weeks), or bi-weekly irinotecan monotherapy (150 mg m^−2^), with or without molecular targeted agents and irrespective of the treatment line. The recommended dose of irinotecan for FOLFIRI is 150 mg m^−2^ for Japanese, which is less than the 180 mg m^−2^ dose recommended for Caucasians, and the recommended treatment schedule in Japan (150 mg m^−2^, on day 1, repeated every 2 weeks) differs from that in Europe and the US (350 mg m^−2^, on day 1, repeated every 3 weeks). Eligible patients also had to have adequate bone marrow reserve and liver and renal functions and provide written informed consent before enrolment. Patients were excluded if they had conditions precluding the use of irinotecan-based regimens, an Eastern Cooperative Oncology Group (ECOG) PS of 3 or 4, or a history of pelvic irradiation. The protocol was reviewed and approved by an independent ethics committee or the institutional review board of each participating centre. The study was conducted in accordance with the Declaration of Helsinki and local ethical and legal requirements. This observational study was registered with the website <http://www.ClinicalTrials.gov> (reference identification: NCT 01039506) and the website <http://www.clinicaltrials.jp/> (reference identification: JapicCTI-090945).

Treatment and evaluation of safety
----------------------------------

The choice of treatment regimen and dosage was left to the investigator\'s discretion. As described previously, 4 weeks of treatment was considered 1 cycle for FOLFIRI ([@bib26]), IRIS ([@bib26]; [@bib16]), or irinotecan monotherapy ([@bib34]), and 3 weeks of treatment was considered 1 cycle for SIR ([@bib6]). Relative dose-intensity was defined as the ratio of the cumulative administered dose to the scheduled total dose for the first 3 cycles of treatment ([@bib34]; [@bib6]; [@bib26]; [@bib16]). The *UGT1A1* genetic profiles were categorised into three groups as described previously ([@bib32]): wild-type (*\*1/\*1*), heterozygous (*\*1/\*6*, *\*1/\*28*), and homozygous (*\*6/\*6*, *\*6/\*28*, *\*28/\*28*). Clinical findings and laboratory tests were evaluated every 2 weeks during the first 3 cycles. (Evaluations at the times of drug administration were mandatory.) After the first 3 cycles, evaluations for safety were performed according to standard clinical practice. Baseline data at registration and detailed toxicities during the first 3 cycles were prospectively recorded via a web-based electronic data collection system. The types and severities of adverse events were graded according to the National Cancer Institute\'s Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0, and the highest grade of each adverse event was recorded. Safety analyses focused on neutropenia and diarrhoea because these are the most common dose-limiting toxicities associated with irinotecan-based regimens ([@bib1]; [@bib11]; [@bib17]).

Statistical analysis
--------------------

The relative risk (RR) of grade 3 or 4 neutropenia or diarrhoea in the heterozygous or homozygous groups was calculated as compared with that in the wild-type group. Fisher\'s exact test was used for group comparisons.

Nomogram model building and validation
--------------------------------------

Multivariable logistic regression analysis was performed to examine the relations of various factors to the occurrence of severe neutropenia of grade 3 or 4 in the first cycle. The multivariable logistic regression model included the following factors: treatment line (first, second, or later line), regimen (FOLFIRI, irinotecan+S-1, or irinotecan monotherapy), administered dose of irinotecan, gender, age, *UGT1A1* genotype (wild-type, heterozygous, or homozygous), ECOG PS (0, 1, or 2), molecular targeted agents, prior surgery, prior radiation, pre-treatment absolute neutrophil count, and pre-treatment total bilirubin level, based on previous reports ([@bib11]; [@bib22]; [@bib28]; [@bib12]; [@bib10]; [@bib17]; [@bib19]; [@bib24]; [@bib35]). Missing values for the pre-treatment absolute neutrophil count (*n*=68, 5.2%) and total bilirubin levels (*n*=127, 9.7%) were imputed by median imputation ([@bib18]) for each *UGT1A1* genotype. All categorical predictors were modelled using dummy variables, while all continuous predictors were modelled using restricted quadratic splines ([@bib7]) based on 2 knots for the tertiles to relax linearity assumptions. The final model was chosen on the basis of variables that had *P*\<0.10 on a backward step-down selection process.

Nomogram validation consisted of discrimination and calibration. Discrimination refers to a nomogram model\'s ability to correctly distinguish two classes of outcomes. First, for internal validation, we used both a bootstrap method with 1000 resamples and a 10-fold cross-validation with 200 repetitions to estimate the bias-corrected or over-fitting corrected predictive accuracy of the model, which is expressed as the concordance index (c-index). Second, we assessed calibration, which compares the predicted probability with the observed outcome in 10 groups partitioned by the decile of the predicted probabilities.

External validation was performed by applying the prediction model to an independent cohort of 350 patients with advanced colorectal cancer who met the same eligibility criteria as the original cohort and were from six independent sites in Japan. The protocol for external validation was also reviewed and approved in each institution. Discriminative power and calibration in the independent cohort were also evaluated.

SAS version 9.2 (SAS Institute, Cary, NC, USA) was used to perform all statistical analyses. All *P* values were two-sided, and *P* values of\<0.05 were considered to indicate statistical significance.

Results
=======

Patient and treatment characteristics
-------------------------------------

Between October 2009 and March 2012, a total of 1376 patients were enrolled. Sixty-four patients were excluded for the following reasons: 42 had no case report forms submitted by the investigators; 15 did not receive irinotecan-based regimens; 4 patients did not meet the inclusion criteria; and 3 withdrew consent after registration. Data from the remaining 1312 patients were included in safety analysis and nomogram development. The baseline characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The *UGT1A1* genotype was wild-type in 47.9% of the patients, heterozygous in 41.1%, and homozygous in 11.1%. Nearly 80% of the patients received irinotecan-based regimens as second- or later-line chemotherapy. The rate of received regimen type was similar among the three groups according to the *UGT1A1* genotype. Similar to a previous study ([@bib29]; [@bib19]), the median pre-treatment total bilirubin level was higher in the homozygous group (0.80 mg dl^−1^) than in the wild-type and heterozygous groups (both 0.60 mg dl^−1^).

The median administered dose of irinotecan in the first cycle of FOLFIRI was approximately 150 mg m^−2^ in the wild-type and heterozygous groups, as compared with 122.5 mg m^−2^ in the homozygous group, which is nearly 20% less than the recommended dose for FOLFIRI in Japan (150 mg m^−2^) ([@bib26]) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). In patients given FOLFIRI, the 3-cycle relative dose-intensities of irinotecan in the homozygous group (55.9%) were lower than those in the wild-type (66.3%) and heterozygous groups (64.1%), irrespective of regimen.

Safety
------

The incidences of grade 3 or 4 neutropenia in the first cycle and entire treatment cycle (up to the third cycle) were, respectively, 18.9% and 25.2% in the wild-type group, 26.5% and 34.1% in the heterozygous group, and 42.1% and 49.0% in the homozygous group ([Figure 1](#fig1){ref-type="fig"}). Severe neutropenia of grade 3 or 4 was more common in the homozygous group (RR, 2.220; *P*\<0.0001 in the first cycle; RR, 1.946; *P*\<0.0001 in the entire cycle) and heterozygous group (RR, 1.400; *P*=0.0024 in the first cycle; RR, 1.357; *P*=0.0010 in the entire cycle) than in the wild-type group.

Febrile neutropenia developed in 30 (2.3%) of the 1312 eligible patients (11 patients in the wild-type group, 9 in the heterozygous group, and 10 in the homozygous group).

The incidences of grade 3 or 4 diarrhoea in the entire cycle were 4.0%, 3.3%, and 7.6% in the wild-type, heterozygous, and homozygous group, respectively ([Figure 2](#fig2){ref-type="fig"}). The incidence of severe diarrhoea was significantly higher in the homozygous group (5.5%) than in the wild-type group (2.1%) only in the first cycle (RR, 2.665; *P*=0.0405).

The incidences of severe toxicities in the homozygous group decreased in parallel to the number of treatment cycles (incidences of neutropenia and diarrhoea: 42.1% and 5.5% in first cycle, 23.9% and 1.8% in second cycle, and 14.4% and 2.1% in third cycle, respectively).

Nomogram development based on the final prediction model and validation
-----------------------------------------------------------------------

The results of multivariable logistic regression analysis of factors potentially related to severe neutropenia in first cycle of irinotecan-based regimens are shown in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. After backward step-down variable selection, treatment line, molecular targeted agents, prior surgery, and prior radiation were excluded from the final prediction model.

The final prediction model for severe neutropenia in the first cycle of irinotecan-based regimens is shown in [Table 2](#tbl2){ref-type="table"}. Significant factors (*P*\<0.10) included regimen (FOLFIRI *vs* irinotecan+S-1 *vs* irinotecan monotherapy), administered dose of irinotecan, gender (male *vs* female), age, *UGT1A1* genotype (wild-type *vs* heterozygous *vs* homozygous), ECOG PS (0 *vs* 1 *vs*≥2), pre-treatment absolute neutrophil count, and pre-treatment total bilirubin level.

The bootstrap-corrected c-index and the c-index after 10-fold cross-validation were 0.693 and 0.668, respectively. The nomogram for predicting the probability of severe neutropenia during the first cycle of irinotecan-based regimens was internally validated as shown in [Figure 3](#fig3){ref-type="fig"}. The bootstrap-corrected calibration slope in the internal cohort is shown in [Figure 4](#fig4){ref-type="fig"}, which indicated good agreement between the predicted and observed probabilities of severe neutropenia.

Using data from an independent cohort set (*n*=350), we attempted to validate the nomogram externally. The incidence of severe neutropenia was 25.7% in the external validation cohort. Patients\' characteristics were similar in the internal and external validation cohorts, with the exceptions of PS and regimens ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). The nomogram also demonstrated good accuracy for predicting the risk of severe neutropenia in the external validation cohort, with a c-index of 0.702. The calibration slope in the external validation cohort was 1.1907, and the intercept −0.0295.

Discussion
==========

We studied the relation between the safety of irinotecan-based regimens and *UGT1A1* genotype and developed a nomogram to predict the risk of irinotecan-induced severe neutropenia in 1312 advanced colorectal cancer patients registered in a prospective observational study. To our knowledge, our study is the largest prospective study of its type to be performed in Asia; moreover, this is the first nomogram to be validated internally and externally.

Our pre-planned interim analysis of safety confirmed that the *UGT1A1* homozygous and heterozygous genotypes were associated with a higher risk of severe neutropenia than the *UGT1A1* wild-type genotype, consistent with the results of many previous studies ([@bib1]; [@bib11]; [@bib22]; [@bib28]; [@bib12]; [@bib10]; [@bib25]; [@bib17]; [@bib19]; [@bib13]; [@bib24]; [@bib3]). In safety results, regardless of the *UGT1A1* genotype, the subject incidence of severe neutropenia successively decreased in the second and third treatment cycles ([Figure 1](#fig1){ref-type="fig"}). This decreasing incidence might have resulted from dose or schedule modifications at the physician\'s discretion, mainly based on the severity of neutropenia in the previous cycle. Moreover, the homozygous genotype was associated with a two-fold (RR, 2.220) higher risk of severe neutropenia in the first course as compared with wild-type, despite using a lower starting dose in the homozygous group. This finding suggests that the risk of severe neutropenia induced by irinotecan-based regimens cannot be predicted solely on the basis of *UGT1A1* genotype and the administered dose of irinotecan; potential effects of other non-genetic factors such as patients\' clinical characteristics must also be considered.

The resulting nomogram demonstrated good accuracy for predicting the probability of severe neutropenia in the first cycle, with a bootstrap-corrected c-index of 0.693 and 0.702 for the internal and external validation cohorts, respectively. The c-index of 0.70 in the external validation cohort indicates that the accuracy of the nomogram for predicting severe neutropenia is 70%, which is considered a clinically meaningful value. Additionally, the *UGT1A1* genotype was the strongest predictor of severe neutropenia among factors included in the final prediction model. In the internal cohort, when only *UGT1A1* genotype was used, the bootstrap-corrected c-index was 0.593 in the prediction model for severe neutropenia in the first cycle of irinotecan-based regimens (odds ratio, 1.545; *P=*0.0020 for heterozygous *vs* wild-type; odds ratio, 3.106; *P*\<0.0001 for homozygous *vs* wild-type) (data not shown). The unacceptable discriminative power of the prediction model including only the *UGT1A1* genotype suggests that our comprehensive approach incorporating non-genetic factors provides a more accurate prediction of the risk of severe neutropenia.

A prediction model for severe neutropenia was constructed only for the first cycle, using eight factors chosen by the multivariable logistic regression model ([Table 2](#tbl2){ref-type="table"}). We could not construct a prediction model for severe diarrhoea or febrile neutropenia owing to the limited number of patients with such toxicity. Although the total bilirubin level at the start of the first cycle was associated with the *UGT1A1* genotype, both factors were independent predictors. In agreement with our findings, [@bib13] reported that both the bilirubin level and *UGT1A1* genotype were significant factors in a model including pre-treatment data to predict the risk of severe neutropenia, suggesting that each added predictive value.

Clinically, this internally and externally validated nomogram will most likely be useful for predicting the probability of irinotecan-induced severe neutropenia in patients with colorectal cancer. If the probability of severe neutropenia exceeds the clinically permissible range (e.g., ≥70%), the starting dose of irinotecan should be reduced. The *UGT1A1* genotype-directed dosing of irinotecan has been evaluated in patients receiving irinotecan-based therapy ([@bib36]; [@bib23]) or irinotecan monotherapy ([@bib32]; [@bib14]). Patients with a low probability of severe neutropenia (e.g., \<30%) as calculated with the nomogram using the standard dose of irinotecan can tolerate substantially higher doses. The concept of nomogram-based dosing of irinotecan should be explored in future clinical trials.

The association between the *UGT1A1* genotype and severe diarrhoea remains controversial ([@bib17]). Most of the previous studies retrospectively evaluated relatively small numbers of patients with different types of cancer who received various irinotecan-based regimens, although the *UGT1A1\*28/\*28* genotype was associated with a two-fold higher risk of diarrhoea than wild-type genotype in a meta-analysis limited to Caucasians with colorectal cancer ([@bib21]). In our study, severe diarrhoea was significantly more common in the homozygous group than in the wild-type group only in the first cycle (RR, 2.665) ([Figure 2](#fig2){ref-type="fig"}). The significant association between severe diarrhoea and the *UGT1A1* genotype in our study is attributed to focusing on 1312 patients with advanced colorectal cancer who received three irinotecan-based regimens, supporting that the *UGT1A1* genotype may serve as a predictive marker for irinotecan-induced severe diarrhoea.

Our study had several limitations. First, our results are applicable to only Asians, because the recommended doses and schedules of irinotecan-based regimens differ between Japan and Western countries, S-1 is frequently used in Asia, and the *UGT1A1\*6* allele is not found in Caucasians. Second, polymorphisms other than *UGT1A1\*6* or *UGT1A1\*28*, such as *UGT1A7*, *UGT1A9* ([@bib2]; [@bib8]; [@bib9]), *ABCB1*, *ABCC2*, *ABCG2*, and *SLCO1B1*, have been suggested to be associated with toxicities induced by irinotecan-based regimens ([@bib13]; [@bib30]). Third, our nomogram can only be used to estimate the probability of irinotecan-induced severe neutropenia, but not efficacy. Although several meta-analyses have examined the correlation between *UGT1A1* genotype and the efficacy of irinotecan-based regimens, including tumour response and survival ([@bib27]; [@bib4]; [@bib20]; [@bib5]), their results remain controversial. The results of our final analysis of outcomes, scheduled to be available in 2015, are expected to shed light on these and other unresolved issues.

In conclusion, our study provides pivotal evidence supporting the association between the *UGT1A1* genotype and an increased risk of irinotecan-induced severe neutropenia and diarrhoea in Japanese patients with colorectal cancer. We developed and validated a clinically useful nomogram including *UGT1A1* genotype and other non-genetic factors for predicting the risk of severe neutropenia in the first cycle of irinotecan-based chemotherapy. We believe that our study represents a great step toward the goal of precision medicine based on irinotecan pharmacogenetics.
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![**Subject incidences of grade 3 or 4 neutropenia according to *UGT1A1* genotype.** Green, yellow, and pink bars represent the incidences for patients harbouring *UGT1A1* wild-type (*\*1/\*1*), heterozygous (*\*1/\*6*, *\*1/\*28*), and homozygous (*\*6/\*6*, *\*6/\*28*, *\*28/\*28*) genotypes, respectively. Abbreviation: RR=relative risk.](bjc2015122f1){#fig1}

![**Subject incidences of grade 3 or 4 diarrhoea according to *UGT1A1* genotype.** Green, yellow, and pink bars represent the incidences for patients harbouring *UGT1A1* wild-type (*\*1/\*1*), heterozygous (*\*1/\*6*, *\*1/\*28*), and homozygous (*\*6/\*6*, *\*6/\*28*, *\*28/\*28*) genotypes, respectively. Abbreviation: RR=relative risk.](bjc2015122f2){#fig2}

![**Nomogram for predicting the probability of irinotecan-induced severe neutropenia in the first cycle.** To calculate the probability of severe (grade 3 or 4) neutropenia, first determine the value for each factor by drawing a vertical line from that factor to the point scale. Then, sum all individual values and draw a vertical line from the total point scale to the probability of severe neutropenia.](bjc2015122f3){#fig3}

![**Nomogram model calibration curve for the internal validation cohort (*n*=1312).** Black line represents ideal fit, where the nomogram-predicted probability (*x*-axis) matches the observed probability (*y*-axis). Closed circles and vertical bars represent the observed probabilities and 95% CI for 10 groups partitioned by the decile of the predicted probabilities. The bootstrap-corrected calibration slope of the regression line in the internal cohort is 1.0026 (95% CI; 0.8053, 1.2038), with an intercept of −0.0005 (95% CI; −0.0485, 0.0428). Abbreviation: CI=confidence interval.](bjc2015122f4){#fig4}

###### Baseline characteristics

                                                   ***UGT1A1*** **genotype group**                                          
  ----------------------------------------------- --------------------------------- ------------------- ------------------- -------------------
  **Median age, years (IQR)**                                67 (61, 73)                66 (60, 73)         68 (61, 74)         67 (61, 73)
  **Gender,** ***n*** **(%)**                                                                                               
  Male                                                       371 (59.1)                 362 (67.2)           85 (58.6)          818 (62.3)
  Female                                                     257 (40.9)                 177 (32.8)           60 (41.4)          494 (37.7)
  **Median BSA, m**^**2**^ **(IQR)**                      1.52 (1.40, 1.66)          1.57 (1.44, 1.68)   1.54 (1.39, 1.67)   1.54 (1.42, 1.67)
  ***UGT1A1* genetic profile, *n* (%)**                                                                                     
  Wild-type group                                                                                                                     
   *\*1/\*1*                                                 628 (100.0)                                                        628 (47.9)
  Heterozygous group                                                                    539 (100.0)                             539 (41.1)
   *\*1/\*6*                                                                            308 (57.1)                              308 (23.5)
   *\*1/\*28*                                                                           231 (42.9)                              231 (17.6)
  Homozygous group                                                                                          145 (100.0)         145 (11.1)
   *\*6/\*6*                                                                                                 50 (34.5)           50 (3.8)
   *\*28/\*28*                                                                                               23 (15.9)           23 (1.8)
   *\*6/\*28*                                                                                                72 (49.7)           72 (5.5)
  **ECOG PS, *n* (%)**                                                                                                      
  0                                                          457 (72.8)                 401 (74.4)          109 (75.2)          967 (73.7)
  1                                                          142 (22.6)                 118 (21.9)           29 (20.0)          289 (22.0)
  2                                                           29 (4.6)                   20 (3.7)             7 (4.8)            56 (4.3)
  **Treatment line, *n* (%)**                                                                                               
  First                                                      138 (22.0)                 125 (23.2)           21 (14.5)          284 (21.6)
  Second or later                                            490 (78.0)                 414 (76.8)          124 (85.5)          1028 (78.4)
  **Regimen, *n* (%)**                                                                                                      
  FOLFIRI                                                    395 (62.9)                 349 (64.7)           96 (66.2)          840 (64.0)
  Irinotecan+S-1                                             160 (25.5)                 132 (24.5)           32 (22.1)          324 (24.7)
  Irinotecan monotherapy                                      73 (11.6)                  58 (10.8)           17 (11.7)          148 (11.3)
  **Molecular targeted agents, *n* (%)**                                                                                    
  None                                                       236 (37.6)                 209 (38.8)           51 (35.2)          496 (37.8)
  Anti-VEGF mAb                                              274 (43.6)                 223 (41.4)           64 (44.1)          561 (42.8)
  Anti-EGFR mAb                                              118 (18.8)                 107 (19.9)           30 (20.7)          255 (19.4)
  **Prior therapy, *n* (%)**                                                                                                
  Surgery                                                    526 (83.8)                 456 (84.6)          116 (80.0)          1098 (83.7)
  Radiation                                                   46 (7.3)                   38 (7.1)            15 (10.3)           99 (7.5)
  Chemotherapy                                               481 (76.6)                 417 (77.4)          121 (83.4)          1019 (77.7)
  Median WBC, 10^2^ mm^−3^ (IQR)                          53.5 (42.6, 66.8)          53.5 (42.0, 69.0)   52.0 (41.3, 63.5)   53.0 (42.0, 67.0)
  Median ANC, 10^2^ mm^−3^ (IQR)                          31.3 (23.0, 41.7)          31.6 (23.3, 42.5)   31.0 (24.0, 41.0)   31.3 (23.1, 42.0)
  Median platelet, 10^4^ mm^−3^ (IQR)                     18.7 (14.3, 24.4)          19.1 (14.6, 24.0)   18.3 (14.5, 23.5)   18.8 (14.5, 24.1)
  Median total bilirubin level, mg dl^−1^ (IQR)           0.60 (0.40, 0.77)          0.60 (0.50, 0.87)   0.80 (0.60, 1.20)   0.60 (0.46. 0.80)

Abbreviations: ANC=absolute neutrophil count; BSA=body surface area; ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; FOLFIRI=folinic acid, fluorouracil, and irinotecan; IQR=interquartile range; mAb=monoclonal antibody; *UGT1A1*=uridine diphosphate glucuronosyltransferase 1A1; VEGF=vascular endothelial growth factor; WBC=white blood cells.

###### Final prediction model based on multivariable logistic regression analysis for severe neutropenia in the first cycle (*N*=1312)

                                                                                                    **Odds ratio**                                          
  ----------------------------------------------------------------------------- ------ ------------ ---------------- ---------------- ---------- ---------- ---------------
  Regimen                                                                                                                                                    0.693 (0.668)
  FOLFIRI                                                                       840    241 (28.7)   1                ---                         0.0015             
  Irinotecan+S-1                                                                324    53 (16.4)    0.546            (0.375, 0.794)   0.0015                        
  Irinotecan monotherapy                                                        148    29 (19.6)    0.579            (0.367, 0.914)   0.0190                        
  Administered irinotecan dose (mg m^−2^)[b](#t2-fn3){ref-type="fn"}            1312   323 (24.6)   ---              ---              ---        0.0024             
  **Gender**                                                                                                                                                
  Male                                                                          818    184 (22.5)   0.686            (0.521, 0.902)   0.0070     0.0070             
  Female                                                                        494    139 (28.1)   1                ---              ---                           
  Age (years)[b](#t2-fn3){ref-type="fn"}                                        1312   323 (24.6)   ---              ---              ---        0.0478             
  ***UGT1A1* genotype**                                                                                                                                     
  Wild-type                                                                     628    119 (18.9)   1                ---              ---        \<0.0001           
  Heterozygous                                                                  539    143 (26.5)   1.624            (1.217, 2.167)   0.0010                        
  Homozygous                                                                    145    61 (42.1)    3.343            (2.191, 5.100)   \<0.0001                      
  **ECOG PS**                                                                                                                                               
  0                                                                             967    228 (23.6)   1                ---              ---        0.0811             
  1                                                                             289    80 (27.7)    1.330            (0.968, 1.828)   0.0787                        
  2                                                                             56     15 (26.8)    1.749            (0.893, 3.429)   0.1034                        
  Pre-treatment ANC (mm^−3^)[b](#t2-fn3){ref-type="fn"}                         1312   323 (24.6)   ---              ---              ---        0.0005             
  Pre-treatment total bilirubin level, (mg dl^−1^)[b](#t2-fn3){ref-type="fn"}   1312   323 (24.6)   ---              ---              ---        0.0003             

Abbreviations: ANC=absolute neutrophil count; c-index=concordance index; 95% CI=95% confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; FOLFIRI=folinic acid, fluorouracil, and irinotecan; *UGT1A1*=uridine diphosphate glucuronosyltransferase 1A1.

Bootstrap-corrected c-index (c-index from 10-fold cross-validation).

Restricted quadratic splines; odds ratios not applicable.
